Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets

A. Fortini, P. A. Modesti, R. Abbate, G. F. Gensini, G. G. Neri Serneri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.

Original languageEnglish
Pages (from-to)319-328
Number of pages10
JournalThrombosis Research
Volume40
Issue number3
DOIs
Publication statusPublished - Nov 1 1985

Fingerprint

Prostaglandin D2
Epoprostenol
Heparin
Blood Platelets
Binding Sites
Platelet Count
Platelet Aggregation
Suspensions
Healthy Volunteers

Keywords

  • Heparin
  • Platelet
  • Prostacyclin
  • Prostaglandin D2
  • Receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Fortini, A., Modesti, P. A., Abbate, R., Gensini, G. F., & Neri Serneri, G. G. (1985). Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets. Thrombosis Research, 40(3), 319-328. https://doi.org/10.1016/0049-3848(85)90267-1

Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets. / Fortini, A.; Modesti, P. A.; Abbate, R.; Gensini, G. F.; Neri Serneri, G. G.

In: Thrombosis Research, Vol. 40, No. 3, 01.11.1985, p. 319-328.

Research output: Contribution to journalArticle

Fortini, A, Modesti, PA, Abbate, R, Gensini, GF & Neri Serneri, GG 1985, 'Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets', Thrombosis Research, vol. 40, no. 3, pp. 319-328. https://doi.org/10.1016/0049-3848(85)90267-1
Fortini, A. ; Modesti, P. A. ; Abbate, R. ; Gensini, G. F. ; Neri Serneri, G. G. / Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets. In: Thrombosis Research. 1985 ; Vol. 40, No. 3. pp. 319-328.
@article{6088be27148d4b0d9abe83420c8fd259,
title = "Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets",
abstract = "Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.",
keywords = "Heparin, Platelet, Prostacyclin, Prostaglandin D2, Receptor",
author = "A. Fortini and Modesti, {P. A.} and R. Abbate and Gensini, {G. F.} and {Neri Serneri}, {G. G.}",
year = "1985",
month = "11",
day = "1",
doi = "10.1016/0049-3848(85)90267-1",
language = "English",
volume = "40",
pages = "319--328",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets

AU - Fortini, A.

AU - Modesti, P. A.

AU - Abbate, R.

AU - Gensini, G. F.

AU - Neri Serneri, G. G.

PY - 1985/11/1

Y1 - 1985/11/1

N2 - Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.

AB - Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.

KW - Heparin

KW - Platelet

KW - Prostacyclin

KW - Prostaglandin D2

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=0022348483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022348483&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(85)90267-1

DO - 10.1016/0049-3848(85)90267-1

M3 - Article

C2 - 3001968

AN - SCOPUS:0022348483

VL - 40

SP - 319

EP - 328

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -